Institut Català d'Oncologia

Bladder-Preserving Treatment Shows Promise: Radiation Plus Dual Immunotherapy Achieves 93% Complete Response in MIBC

- A novel combination of radiation therapy with durvalumab and tremelimumab immunotherapy achieved a 93% complete response rate in muscle-invasive bladder cancer patients, offering a promising bladder-preserving alternative. - The IMMUNOPRESERVE trial demonstrated strong efficacy with 30 out of 32 patients maintaining their bladders after a median follow-up of 27 months, with 84% two-year overall survival rate. - The treatment regimen showed manageable safety profile with 31% grade 3-4 adverse events, presenting a potential alternative to radical cystectomy for eligible patients.